Roche gets antitrust objections in Belgian probe of cancer drugs
Roche Group is the target of formal antitrust charges by the Belgian competition authority over a strategy to hamper competitive tenders and share false information about rival biosimilar drugs. The substances...To view the full article, register now.
Already a subscriber? Click here to view full article